Market evolution: Enzymes (CN 35079090) — 2015–2025

Introduction

This report analyses the EU's external trade in enzymes and prepared enzymes not elsewhere specified (CN 35079090) over the period 2015–2025. The product heading covers a broad range of industrial enzymes — used in food processing, biofuels, detergents, textiles, and pharmaceuticals — excluding rennet, lipoprotein lipase, and Aspergillus alkaline protease. The EU is one of the world's leading producers and exporters of industrial enzymes, with Denmark serving as the dominant hub thanks to the presence of major enzyme manufacturers.

Over the decade under review, the EU's enzyme trade expanded significantly in value terms while remaining broadly stable in volume, reflecting structural shifts toward higher-value, specialised enzyme products. The analysis draws on trade flows between the EU and non-EU countries, covering overall trade dynamics, partner-level breakdowns, market concentration, and vulnerability indicators.

1. A Robust Export Powerhouse with Expanding Margins

1.1 EU exports grew in value by nearly half while volumes remained broadly stable

Between 2015 and 2025, EU exports of enzymes rose from €1.48 billion to €2.17 billion, a gain of 46.2%. Over the same period, export volumes increased only modestly, from 132,956 tonnes to 148,383 tonnes (+11.6%). The gap between the two growth rates is explained by a sharp rise in unit export prices, which climbed from €11,160 per tonne to €14,621 per tonne (+31.0%). This pattern suggests that the EU's competitive edge lies increasingly in high-value, application-specific enzyme blends rather than in volume growth alone.

1.2 EU production of enzymes nearly doubled in quantity and tripled in value

Domestic production data reinforces this picture of a sector moving up the value chain. EU production of enzymes rose from 150.7 million kg to 271.0 million kg (+79.9%) in quantity terms, and from €851 million to €2.49 billion (+193.0%) in value terms. The fact that production value grew more than three times as fast as production quantity indicates a structural shift toward premium products — likely driven by innovation in food-tech, bio-based chemicals, and sustainable manufacturing applications.

1.3 The trade surplus widened to over €1.5 billion

The EU consistently maintained a large positive trade balance throughout the period. The surplus expanded from €1.05 billion in 2015 to €1.50 billion in 2025 (+43.0%), peaking at €1.68 billion at its highest point. This persistent and growing surplus underscores the EU's structural role as a net exporter of enzyme technology to the rest of the world.

2. Shifting Geographic Orientations: Emerging Markets Gain Weight

2.1 The United States and China consolidated their position as the EU's top two export markets

The United States remained by far the EU's largest single export destination, absorbing €534 million in 2025 (up 28.0% from €417 million). China was the second-largest partner, with exports rising from €112 million to €156 million (+39.3%). Together, these two markets accounted for roughly one-third of total extra-EU enzyme exports, reflecting the importance of large-scale food, feed, and bio-industrial demand in both countries.

2.2 Türkiye, Brazil, and India emerged as fast-growing destinations

The most striking growth dynamics occurred in a set of emerging markets:

India stands out with a remarkable +176.2% increase, driven by the country's expanding food-processing, textile, and biofuel industries. Türkiye and Brazil also nearly doubled their imports of EU enzymes, likely reflecting industrialisation and the adoption of enzyme-based solutions in agriculture and manufacturing. The UK, despite Brexit-related disruptions, saw its EU enzyme imports rise by 30.2% — though its share may have been affected by new customs procedures.

2.3 Russia's share declined amid geopolitical tensions

EU exports to the Russian Federation fell from €75 million to €55 million (-26.4%), reversing an earlier peak of €140 million. This decline accelerated after 2022 and is consistent with the broader pattern of EU–Russia trade contraction following the imposition of sanctions and counter-sanctions.

2.4 EU import sourcing shifted toward the US and China, away from the UK

On the import side, the United States nearly doubled its share of EU enzyme imports, rising from €155 million to €306 million (+97.7%). China more than doubled its position, climbing from €66 million to €133 million (+100.9%). In contrast, the United Kingdom saw its exports to the EU fall from €52 million to €29 million (-44.8%), a decline likely driven by post-Brexit regulatory divergence and increased trade friction. Mexico's share collapsed by 70.4%, suggesting a loss of competitiveness or a restructuring of supply chains.

2.5 Import concentration increased markedly while export markets diversified

The Herfindahl-Hirschman Index (HHI) for EU imports by value rose from 1,979 to 2,869 (+45.0%), indicating that import sourcing became significantly more concentrated around a smaller number of suppliers — primarily the US and China. By contrast, the export-side HHI fell from 1,029 to 862 (-16.2%), suggesting that EU exporters successfully diversified their customer base across a broader range of countries. This asymmetry is noteworthy: while the EU's export market base broadened, its import supply chain became more dependent on two major partners.

3. Structural Shifts in EU Trade Openness and Selective Price Volatility

3.1 The EU's net export position intensified dramatically

The EU's net import reliance — a measure expressing the trade balance as a percentage of total trade — moved from −88.0% to −173.6%. Negative values indicate a net exporter, and the deepening of this figure confirms that the EU became an even more dominant net supplier of enzymes to world markets. The extreme magnitude (a value of −173.6% in 2025) reflects a situation where exports far outstripped imports, consistent with the EU's position as the global centre of enzyme innovation and manufacturing.

3.2 Trade intensity and export propensity both reached record highs

The EU's trade intensity (total trade as a share of production) rose from 82.7% to 90.1%, indicating that an increasingly large share of EU-produced enzymes entered international trade. The export propensity (exports as a share of production) climbed from 77.4% to 87.7%. Both indicators point to a sector that is deeply integrated into global value chains and increasingly outward-looking.

3.3 Price shocks were isolated but notable in specific bilateral flows

The overall volatility of EU enzyme trade was relatively contained, but the analysis detected specific shock events:

The 2021 price spike in EU exports to India (abnormality score of 232.6) and imports from China (abnormality of 21.0) coincides with the post-COVID commodity supercycle and global supply-chain disruptions that affected input costs across the bio-chemical sector. The 2022 Indonesia event, while more modest in scale, may reflect the region's growing role as a downstream consumer of specialty enzymes for palm-oil processing and oleochemicals.

3.4 Denmark remained the undisputed EU hub, but the Netherlands surged

Among EU Member States, Denmark accounted for the lion's share of exports, rising from €557 million to €801 million (+44.0%), reflecting its role as the home of leading enzyme producers. Germany remained the second-largest exporter (€317 million). The most dramatic shift occurred in the Netherlands, whose exports nearly tripled from €167 million to €403 million (+141.6%), potentially reflecting expansion of production facilities or increased activity of enzyme distributors and trading houses based in Dutch ports.

On the specialisation front, Denmark recorded a Revealed Symmetric Comparative Advantage (RSCA) of 0.89 in 2025, confirming its exceptional specialisation in enzyme exports. Finland (RSCA 0.82) and Lithuania (RSCA 0.37) also showed notable specialisation. At the other end of the spectrum, Slovakia (RSCA −0.99) and Romania (RSCA −0.98) were the least specialised, reflecting their lack of domestic enzyme manufacturing capacity.

Conclusion

The EU's trade in enzymes (CN 35079090) over 2015–2025 tells a story of a mature, innovation-driven sector that strengthened its global position through value-added differentiation rather than volume expansion. Export values grew by 46.2% while volumes rose only 11.6%, reflecting a strategic shift toward higher-margin, application-specific enzyme products. The trade surplus widened to over €1.5 billion, and both trade intensity and export propensity reached record highs, confirming the sector's deep integration into global markets.

Geographically, the EU's export footprint broadened, with fast-growing emerging markets — particularly India (+176%), Türkiye (+96%), and Brazil (+77%) — absorbing a rising share of output. At the same time, import sourcing became more concentrated around the United States and China, a dynamic that warrants attention from a supply-chain resilience perspective. Price shocks remained localised but were concentrated in 2021–2022, broadly aligned with post-pandemic cost pressures.

Denmark continued to anchor EU enzyme exports, but the rapid growth of the Netherlands signals a potential redistribution of trade flows within the EU. Looking ahead, the sector's trajectory will likely be shaped by the expansion of enzyme applications in sustainable chemistry, circular economy processes, and precision fermentation — areas where the EU's established R&D base and manufacturing expertise provide a durable competitive advantage.